

Company Overview

OncoSec Medical Incorporated is a biopharmaceutical company developing its investigational immunotherapy, TAVO, for the treatment of cancer. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. In clinical trials to date, we have not observed significant safety issues of concern. Further, we have observed preliminary evidence of anti-tumor activity to suggest the potential of TAVO in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating TAVO for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate TAVO in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.

UCSF Doses First Patient in Triple Combination Clinical Trial of OncoSec's TAVO™, Epcadostat and KEYTRUDA® for the Treatment of Unresectable Squamous Cell Head and Neck Cancer

May 23 2019, 8:30 AM EDT

OncoSec Medical Incorporated Prices \$11,000,000 Public Offering

May 22 2019, 8:45 AM EDT

OncoSec Provides Encouraging Interim Data from Ongoing KEYNOTE-890 Study of TAVO in Combination with KEYTRUDA® for the Treatment of Heavily Pretreated Chemotherapy/Radiotherapy Refractory Metastatic Triple Negative Breast Cancer

May 22 2019, 8:30 AM EDT

Stock Overview

Symbol	ONCS
Exchange	Nasdaq
Market Cap	18.3m
Last Price	\$2.57
52-Week	\$2.68 - \$19.60

05/23/2019 04:00 PM EDT

Investor Relations

T: 855-ONCOSEC (855-662-6732)
investors@oncosec.com

OncoSec Medical Incorporated

24 Main St.
Pennington, NJ 08534

24 Main St.
Pennington, NJ 08534

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.